Analyst Conference Summaries

Biotechnology Investor Aids

Ocata Therapeutics

Ocata to be Bought Buy Astellas for $8.50 per share November 10, 2015

Lucky me. I bought tiny amounts of OCAT in July and August, was thinking about buying more, but alas, had not done so before the announcements. — William Meyers

conference date: November 9, 2015 at 5:30 PM Pacific Time

First Patient Enrolled in Ocata Therapeutics’ Phase 2 Dry AMD Study [Sept. 8, 2015]

Ocata Therapeutics Q2 Results [August 6, 2015]

Note: I will begin analyst conference coverage starting with the Q3 conference

Q1 not available
Q2 not available  

Ocata Therapeutics (OCAT) is a development-stage biotechnology company specializing in cell-based regeneration therapies for the human eye.

Ocata web site



More Analyst Conference Pages:



Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2015 William P. Meyers